This interactive microlearning activity is part of a case-based series designed to engage pathologists, laboratory professionals, and other members of the multidisciplinary cancer care team in improving biomarker testing and treatment for NSCLC. This specific course focuses on exploring emerging biomarkers and antibody validation methods.
Course topics include:
- HER2 in NSCLC
- Antibody validation methods
- Reducing risk in antibody validation and biomarker testing
Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals.
Learning Objectives
Upon completion of this activity, you will be able to:
- Explore the emerging biomarker, HER2, in NSCLC and its implications for the laboratory
- Develop sound antibody validation methods
- Discuss strategies to reduce risk in antibody validation and biomarker testing
Faculty
Jefree Schulte
Director of Surgical Pathology
Assistant Professor (CHS)
University of Wisconsin, Madison, WI
Faculty Disclosures
Dr. Jefree Schulte has no relationships to disclose.
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The ASCP designates this activity for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this activity for a maximum of .25 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.
Method of Participation
To complete the activity and receive credit, the participant must attend the program. CME certificates will be provided on-line.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.